Finance & Capital Markets

  1. Episode 5: Finding Funding In Volatile Times With Ben Zeskind 8/13/2020

    Ben Zeskind launched his biotech, Immuneering, in the throes of the Great Recession. The company earned a $20 million series A round to fund the development of its pipeline at the outset of the COVID-19 pandemic. Along the way, it bootstrapped its way from bioinformatics company to fledgling biopharma. On this episode of The Business Of Biotech, Zeskind shares his experience-based wisdom on finding funding in volatile times.

  2. The Generalist Biotech CEO With Seekyo's Oury Chetboun 7/30/2025

    On this week's Business Of Biotech episode, Oury Chetboun, co-founder and CEO of Seekyo, a French biotech, talks about the range of experiences that prepared him to lead a company focused on developing innovative solid tumor treatments that target functional proteins in the tumor micro-environment.

  3. A Royalty Model For Value Creation With Zymeworks' Kenneth Galbraith 1/8/2026

    On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through partnerships with companies including Jazz Pharmaceuticals and BeOne Medicines (formerly BeiGene), J&J, Merck, Daiichi Sankyo, and GSK.

  4. Embracing Biotech Chaos With Memo's Erik van den Berg 9/8/2024

    Erik van den Berg is CEO and board member at Memo Therapeutics, and he's a student of biotech chaos. In fact, he's been embracing it with intention for the past 30 years. On this episode of the Business of Biotech, he walks us through the management of that chaos in specific detail.

  5. Building On Pandemic Progress With Barinthus Biotherapeutics' Bill Enright 10/27/2024

    It sure seems like Bill Enright has a knack for making big moves at inopportune times, then turning the expected outcome on its ear. For example, he signed on as CEO at Altimmune when the company was struggling mightily. Enright had a turnaround plan in hand, but as he was in the thick of a non-deal road show to execute said plan, Lehmen Brothers collapsed. On this episode of the Business of Biotech, we'll learn how he flipped the script and other harrowing tales from the trenches. 

  6. Biotech C-Suite Construction With Allan Shaw 10/13/2024

    Allan Shaw is back with us this week to dig into the complexities of strategic hiring in biotech. If you're growing a biotech in these volatile times, this episode of the Business of Biotech offers veteran insight you won't want to miss.

  7. Art Of The Pivot With Elevation Oncology's Joe Ferra 1/3/2024

    Relatively new CEO Joseph Ferra has orchestrated some pretty significant change at Elevation Oncology in the two(ish) years since the Business of Biotech last hosted the company. In that short time, Ferra advanced from CFO to CEO, a move that aligned very closely with the company's difficult decision to shelve the late phase 2 anti-HER3 monoclonal antibody candidate it was founded on.

  8. The Implications Of China's Growing Biotech Industry With Allan Shaw 4/16/2025

    Business of Biotech MVP Allan Shaw is back to talk about the rise of China's biotech sector, and its evolution from fast follower to global innovation powerhouse.

  9. A CFO's Prescription For Biopharma Success 3/22/2021

    Friend of the show and life sciences CFO extraordinaire Allan Shaw joins us for a discussion on the steps to biopharma success from an insider's perspective. We discuss the incremental steps that are necessary and common to success in the biologic therapy space, and the mistakes Shaw has seen in his many engagements with new and emerging biotech firms. From capital resource allocation to personnel decision making to preparing for the bubble to burst, listen in as Shaw shares his unfiltered advice.

  10. BoB@JPM: Post-IPO With Bolt Biotherapeutics' Drs. Randall Schatzman and Edith Perez 2/19/2023

    Bolt Biotherapeutics CEO Randall Schatzman, Ph.D. and CMO Edith Perez, M.D. are no strangers to the Business of Biotech, having previously joined us on episodes 14 and 18, respectively. The last time we spoke with Dr. Schatzman, he was preparing the company for its initial public offering. We caught up with him and Dr. Perez at the JP Morgan Healthcare Conference in San Francisco last month for a conversation on the IPO process, the impacts it's had on the go-forward plan at Bolt Bio, the company's clinical progress, and its collaboration strategy moving forward.